Smurfit Kappa Group Total Revenue increased by 1.7% to $7.71B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.7%, from $7.66B to $7.71B. Over 2 years (FY 2022 to FY 2025), Total Revenue shows an upward trend with a 51.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates market expansion or higher demand, while a decrease may signal market saturation or competitive pressure.
Total revenue represents the gross inflow of economic benefits arising from the ordinary operating activities of the com...
Standard across all public companies; peers in the medical device and diagnostics sector typically show steady growth correlated with product adoption.
total_revenue| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.38B | $3.38B | $3.38B | $3.38B | $2.92B | $2.86B | $2.93B | $2.97B | $7.67B | $7.54B | $7.66B | $7.94B | $8.00B | $7.58B | $7.71B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -13.7% | -1.8% | +2.4% | +1.3% | +158.4% | -1.7% | +1.6% | +3.7% | +0.8% | -5.3% | +1.7% |
| YoY Change | — | — | — | — | -13.7% | -15.3% | — | — | +163.2% | +163.4% | +161.3% | +167.4% | +4.3% | +0.5% | +0.7% |
| Segment | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|
| North America | $4.65B | $4.59B | $4.67B | $4.76B | $4.72B | $4.43B | $4.50B |
| Europe, MEA and APAC | $2.65B | $2.52B | $2.58B | $2.78B | $2.83B | $2.70B | $2.77B |
| LATAM | $506.00M | $524.00M | $513.00M | $518.00M | $545.00M | $537.00M | $540.00M |
| Total | $7.67B | $7.54B | $7.66B | $7.94B | $8.00B | $7.58B | $7.71B |
| Segment | FY'24 | FY'25 |
|---|---|---|
| Other Europe, MEA and APAC | $6.20B | $7.17B |
| Other Americas | $2.33B | $3.38B |
| Total | $21.11B | $31.18B |
All segment values are derived from annual filings.